¿Importa la secuencia de tratamiento en egfr +?: Factores que deberían ser considerados

7 / 33

1. Park K et al, Lancet Oncol 2016; 2. Corral J, ELCC 2017; 3. Yang JJ et al. BJC 2017; 4. Tony Mok at ASCO 2017
Trial Drugs Phase N Median
PFS
months
HR Median OS
months
HR
CTONG
09013
Erlotinib
vs Gefitinib
III 256 13.0
vs 10.4
HR 0.81
p= 0.108
22.9 vs 20.1 HR 0.86 [95% CI 0.63–
1.13], p= 0.250
LUX-Lung
71-2
Afatinib
vs Gefitinib
IIb 319 11.0
vs 10.9
HR 0.73
p=0.017
27.8 vs 24.5 HR 0.85 [95% CI 0.66–
1.09], p= 0.195
ARCHER
10504
Dacomitinib
vs Gefitinib
III 452 14.7
vs 9.2
HR 0.59
P < 0.0001
NA NA
Head to head first vs second/third generation TKIs in front line